Company news: J&J's Janssen

Share this article:
An Arkansas judge levied a $1.2 billion fine on Johnson & Johnson's Janssen after a jury there found the pharma giant guilty of downplaying the risks of its antipsychotic Risperdal. The fine is far and away the largest in a statewide case, though judges and juries in South Carolina, Louisiana and Texas have ordered the firm to pay more than three-quarters of a billion dollars in Risperdal cases combined. J&J's Ortho-McNeil and Janssen units are operating under at federal Corporate Integrity Agreement related to Topamax marketing abuses.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.